MYOS Warning on Unregulated Weight-Loss Injections: How to Check a GLP-1 Seller in Malaysia (2026)

In January 2026 the Malaysian Obesity Society (MYOS) issued a public health warning about weight-loss injections being sold through online shopping platforms, social media and other non-medical channels. Two months later, Sinar Daily reported the Ministry of Health's enforcement figures for the same problem. This article sets out what the warning says, what the law is, and a practical checklist you can use before you buy or inject anything.

What MYOS actually said

MYOS's warning concerns GLP-1 receptor agonists and GLP-1/GIP co-agonists sold "through online shopping platforms, social media, and non-medical channels", without prescription or regulatory approval. It lists the specific dangers: products not registered with regulatory agencies, no manufacturing oversight, uncertain purity and potency, and the possibility of incorrect doses or contaminants.

On the clinical side, MYOS names severe nausea, vomiting, dehydration, hypoglycaemia (particularly in people with diabetes on certain medications), pancreatitis and gallbladder disease as risks of using such products without supervision. Its advice is to obtain medication only through legitimate pharmacies after consultation with trained healthcare professionals, to check labels for spelling errors or incorrect addresses that suggest illegitimate production, to avoid unverified online or non-medical sources, and to report illicit sales to the Ministry of Health.

The law: prescription-only, and the numbers behind the enforcement

According to Sinar Daily's report of 5 March 2026, GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide and lixisenatide — are classified as Group B poisons under the Poisons Act 1952. That means they cannot be bought over the counter, from a pharmacy without a prescription, or from an online seller.

The same report gives the Ministry of Health's Pharmacy Enforcement Division figures: in 2025 alone it issued warning letters over 48 social-media advertisements involving Ozempic, Mounjaro and Saxenda and removed one illegal e-commerce listing; between January 2023 and December 2025 it removed 38,055 unapproved medical advertisements from e-commerce platforms and screened 13,070 on social media. A doctor quoted in the article, Dr Ting Pey Woei, warned that unsupervised use risks dosing errors, counterfeit products and serious side effects including nausea, dehydration and kidney injury.

A five-point checklist before you buy or inject anything

1. A named, registered doctor assessed you first. Ask for the doctor's name and MMC registration number and verify it on the Malaysian Medical Council website.
2. You received a prescription. If no one asked about your medical history, weight, other medicines or pregnancy status, that is not a consultation.
3. A licensed pharmacy dispensed the product. Delivery straight from a social-media seller, a "supplier" or an overseas parcel is not a pharmacy.
4. The product is a registered brand with a proper label. Products registered in Malaysia carry a MAL registration number. Be suspicious of vials or pens described as "research peptide", "compounded alternative" or sold without a brand name.
5. The label reads correctly. MYOS specifically advises checking for spelling errors and incorrect addresses — signs of illegitimate production.

If you have already bought one

Do not start, or continue, injecting it without speaking to a doctor. Keep the packaging so the product can be identified, and report the seller to the Ministry of Health, as MYOS advises. If you have already used it and feel unwell — persistent vomiting, severe abdominal pain, signs of dehydration or, if you have diabetes, low blood sugar — seek medical care.

How the legitimate route works

Whether you go to a clinic or use a telehealth service such as Seimbang, the sequence is the same: a registered doctor assesses your eligibility, decides whether a GLP-1 medicine is appropriate, issues a prescription, and a licensed pharmacy dispenses and delivers a registered product. Seimbang's doctors are MMC-registered and named on this site with their registration numbers, and treatment starts from RM899/month with consultations included.

Sources

• Malaysian Obesity Society (MYOS) — Public Health Warning: Unregulated Weight-Loss Medications, 6 January 2026
• Sinar Daily — Online weight-loss drugs evade Malaysia's prescription laws (MOH Pharmacy Enforcement figures), 5 March 2026